Literature DB >> 19195054

Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis.

Maurizia Rossana Brunetto1, Piero Colombatto, Ferruccio Bonino.   

Abstract

The simulation of the dynamics of viral infections by mathematical equations has been applied successfully to the study of viral infections during antiviral therapy. Standard models applied to viral hepatitis describe the viral load decline in the first 2-4 wk of antiviral therapy, but do not adequately simulate the dynamics of viral infection for the following period. The hypothesis of a constant clearance rate of the infected cells provides an unrealistic estimation of the time necessary to reach the control or the clearance of hepatitis B virus (HBV)/hepatitis C virus (HCV) infection. To overcome the problem, we have developed a new multiphasic model in which the immune system activity is modulated by a negative feedback caused by the infected cells reduction, and alanine aminotransferase kinetics serve as a surrogate marker of infected-cell clearance. By this approach, we can compute the dynamics of infected cells during the whole treatment course, and find a good correlation between the number of infected cells at the end of therapy and the long-term virological response in patients with chronic hepatitis C. The new model successfully describes the HBV infection dynamics far beyond the third month of antiviral therapy under the assumption that the sum of infected and non-infected cells remains roughly constant during therapy, and both target and infected cells concur in the hepatocyte turnover. In clinical practice, these new models will allow the development of simulators of treatment response that will be used as an "automatic pilot" for tailoring antiviral therapy in chronic hepatitis B as well as chronic hepatitis C patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19195054      PMCID: PMC2653343          DOI: 10.3748/wjg.15.531

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative.

Authors:  Vassiliki-Anastasia Sypsa; Konstantinos Mimidis; Nicholas C Tassopoulos; Dimitrios Chrysagis; Themistoklis Vassiliadis; Antonios Moulakakis; Maria Raptopoulou; Caterina Haida; Angelos Hatzakis
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

2.  Dynamics of hepatitis B virus clearance in chimpanzees.

Authors:  John M Murray; Stefan F Wieland; Robert H Purcell; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-23       Impact factor: 11.205

3.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

Authors:  A U Neumann; N P Lam; H Dahari; D R Gretch; T E Wiley; T J Layden; A S Perelson
Journal:  Science       Date:  1998-10-02       Impact factor: 47.728

4.  Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa.

Authors:  N P Lam; A U Neumann; D R Gretch; T E Wiley; A S Perelson; T J Layden
Journal:  Hepatology       Date:  1997-07       Impact factor: 17.425

5.  International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.

Authors:  Stefan Zeuzem; Jean-Michel Pawlotsky; Esther Lukasiewicz; Michael von Wagner; Ioannis Goulis; Yoav Lurie; Elia Gianfranco; Jan-Maarten Vrolijk; Juan I Esteban; Christophe Hezode; Martin Lagging; Francesco Negro; Alexandre Soulier; Elke Verheij-Hart; Bettina Hansen; Ronen Tal; Carlo Ferrari; Solko W Schalm; Avidan U Neumann
Journal:  J Hepatol       Date:  2005-08       Impact factor: 25.083

6.  A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.

Authors:  Piero Colombatto; Luigi Civitano; Ranieri Bizzarri; Filippo Oliveri; Somesh Choudhury; Ronald Gieschke; Ferruccio Bonino; Maurizia R Brunetto
Journal:  Antivir Ther       Date:  2006

7.  Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.

Authors:  B Ramratnam; S Bonhoeffer; J Binley; A Hurley; L Zhang; J E Mittler; M Markowitz; J P Moore; A S Perelson; D D Ho
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

Review 8.  New kinetic models for the hepatitis C virus.

Authors:  Alan S Perelson; Eva Herrmann; Florence Micol; Stefan Zeuzem
Journal:  Hepatology       Date:  2005-10       Impact factor: 17.425

9.  Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy.

Authors:  M Tsiang; J F Rooney; J J Toole; C S Gibbs
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

10.  Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells.

Authors:  P Colombatto; P Ciccorossi; A M Maina; L Civitano; F Oliveri; B Coco; V Romagnoli; F Bonino; M R Brunetto
Journal:  Clin Pharmacol Ther       Date:  2008-03-19       Impact factor: 6.875

View more
  10 in total

1.  High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on.

Authors:  Marco Montagnani; Marina Giandinoto; Andrea Lisotti; Silvia Galli; Francesco Azzaroli; Federica Buonfiglioli; Laura Turco; Rita Aldini; Giuseppe Mazzella
Journal:  Dig Dis Sci       Date:  2011-09-01       Impact factor: 3.199

2.  Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.

Authors:  Harel Dahari; Jeremie Guedj; Alan S Perelson; Thomas J Layden
Journal:  Curr Hepat Rep       Date:  2011-07-02

3.  Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.

Authors:  Dong Jin Suh; Soon Ho Um; Eva Herrmann; Ju-Hyun Kim; Young Sok Lee; Heon Ju Lee; Myung Seok Lee; Youn-Jae Lee; Weibin Bao; Patricia Lopez; Han Chu Lee; Claudio Avila; Stefan Zeuzem
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

4.  Acaricide treatment affects viral dynamics in Varroa destructor-infested honey bee colonies via both host physiology and mite control.

Authors:  Barbara Locke; Eva Forsgren; Ingemar Fries; Joachim R de Miranda
Journal:  Appl Environ Microbiol       Date:  2011-10-21       Impact factor: 4.792

5.  On fractional order models for Hepatitis C.

Authors:  E Ahmed; H A El-Saka
Journal:  Nonlinear Biomed Phys       Date:  2010-03-18

6.  On multi-strain model for Hepatitis C.

Authors:  E Ahmed; Ha El-Saka
Journal:  Nonlinear Biomed Phys       Date:  2011-08-03

7.  Development of mathematical models for the analysis of hepatitis delta virus viral dynamics.

Authors:  Bruno C de Sousa; Celso Cunha
Journal:  PLoS One       Date:  2010-09-16       Impact factor: 3.240

8.  HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial.

Authors:  P Colombatto; M R Brunetto; A M Maina; V Romagnoli; P Almasio; M G Rumi; A Ascione; G Pinzello; M Mondelli; L Muratori; R Rappuoli; D Rosa; M Houghton; S Abrignani; F Bonino
Journal:  J Viral Hepat       Date:  2013-08-27       Impact factor: 3.728

9.  A derived honey bee stock confers resistance to Varroa destructor and associated viral transmission.

Authors:  Thomas A O'Shea-Wheller; Frank D Rinkevich; Robert G Danka; Michael Simone-Finstrom; Philip G Tokarz; Kristen B Healy
Journal:  Sci Rep       Date:  2022-04-07       Impact factor: 4.379

10.  Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B.

Authors:  Nancy W Y Leung; Eva Herrmann; George K K Lau; Henry L Y Chan; Tokutei M K So; Stefan Zeuzem; Yu Dong; Aldo Trylesinski; Nikolai V Naoumov
Journal:  Infect Dis Ther       Date:  2014-09-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.